| Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? JT Nauseef, MD Henry Nature reviews Urology 8 (8), 428-439, 2011 | 222 | 2011 |
| Resistance to fluid shear stress is a conserved biophysical property of malignant cells JM Barnes, JT Nauseef, MD Henry PloS one 7 (12), e50973, 2012 | 194 | 2012 |
| Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations JM Mota, E Barnett, JT Nauseef, B Nguyen, KH Stopsack, A Wibmer, ... JCO precision oncology 4, 355-366, 2020 | 112 | 2020 |
| Alterations in cancer cell mechanical properties after fluid shear stress exposure: a micropipette aspiration study VK Chivukula, BL Krog, JT Nauseef, MD Henry, SC Vigmostad Cell health and cytoskeleton, 25-35, 2015 | 79 | 2015 |
| Emerging prostate-specific membrane antigen-based therapeutics: small molecules, antibodies, and beyond JT Nauseef, NH Bander, ST Tagawa European Urology Focus 7 (2), 254-257, 2021 | 14 | 2021 |
| Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition TL Place, JT Nauseef, MK Peterson, MD Henry, JJ Mezhir, FE Domann PLoS One 8 (12), e83021, 2013 | 11 | 2013 |
| The impact of androgen deprivation therapy on COVID-19 illness in men with prostate cancer NJ Shah, VG Patel, X Zhong, L Pina, JE Hawley, E Lin, BA Gartrell, ... JNCI cancer spectrum 6 (3), pkac035, 2022 | 10 | 2022 |
| An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer JT Nauseef, DM Villamar, J Lebenthal, PJ Vlachostergios, ST Tagawa Expert Opinion on Pharmacotherapy 21 (8), 863-870, 2020 | 10 | 2020 |
| Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm JT Nauseef, HI Lim, MT DeSancho Journal of Thrombosis and Thrombolysis 52, 597-600, 2021 | 9 | 2021 |
| The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer. VG Patel, X Zhong, NJ Shah, L Pina Martina, J Hawley, E Lin, BA Gartrell, ... Journal of Clinical Oncology 39 (6_suppl), 41-41, 2021 | 8 | 2021 |
| Platinum-based chemotherapy in metastatic prostate cancer With DNA repair gene alterations. JCO Precis Oncol. 2020; 4: 355–66 JM Mota, E Barnett, JT Nauseef, B Nguyen, KH Stopsack, A Wibmer | 8 | |
| Antibody-drug conjugates for urothelial carcinoma J Thomas, M Sun, T Getz, B Ho, JT Nauseef, ST Tagawa Urologic Oncology: Seminars and Original Investigations, 2023 | 7 | 2023 |
| Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes. JM Mota, E Barnett, J Nauseef, KH Stopsack, AG Wibmer, DC Danila, ... Journal of Clinical Oncology 37 (15_suppl), 5038-5038, 2019 | 6 | 2019 |
| Long-molecule scars of backup DNA repair in BRCA1-and BRCA2-deficient cancers J Setton, K Hadi, ZN Choo, KS Kuchin, H Tian, A Da Cruz Paula, ... Nature 621 (7977), 129-137, 2023 | 4 | 2023 |
| Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in … K Subramanian, J Martinez, S Huicochea Castellanos, J Ivanidze, ... Scientific Reports 13 (1), 8321, 2023 | 4 | 2023 |
| Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591. MP Sun, JT Nauseef, J Palmer, JE Thomas, J Stangl-Kremser, ... Journal of Clinical Oncology 41 (6_suppl), 181-181, 2023 | 4 | 2023 |
| Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer. JT Nauseef, J Osborne, P Gregos, C Thomas, M Bissassar, S Singh, ... Journal of Clinical Oncology 40 (16_suppl), TPS5100-TPS5100, 2022 | 4 | 2022 |
| Prostate-specific membrane antigen–targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: A phase I dose-escalation study of 225Ac-J591 ST Tagawa, C Thomas, AO Sartor, M Sun, J Stangl-Kremser, M Bissassar, ... Journal of Clinical Oncology 42 (7), 842-851, 2024 | 3 | 2024 |
| Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER) AE Marciscano, S Wolfe, XK Zhou, CE Barbieri, SC Formenti, JC Hu, ... BMC cancer 23 (1), 781, 2023 | 3 | 2023 |
| Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta … ST Tagawa, MP Sun, JT Nauseef, C Thomas, S Huicochea Castellanos, ... Journal of Clinical Oncology 41 (16_suppl), 5018-5018, 2023 | 3 | 2023 |
Michael HenryUniversity of Iowa, Carver College of MedicineVerified email at uiowa.edu
